本页面由Tiger Trade Technology Pte. Ltd.提供服务

Emergent Biosolutions

8.01
-0.0400-0.50%
盘后8.010.00000.00%16:10 EDT
成交量:77.91万
成交额:624.05万
市值:4.15亿
市盈率:8.61
高:8.10
开:7.96
低:7.87
收:8.05
52周最高:14.06
52周最低:4.02
股本:5,177.09万
流通股本:5,125.71万
量比:0.79
换手率:1.52%
股息:- -
股息率:- -
每股收益(TTM):0.9300
每股收益(LYR):0.9300
净资产收益率:10.46%
总资产收益率:5.34%
市净率:0.79
市盈率(LYR):8.61

数据加载中...

公司资料

公司名字:
Emergent Biosolutions
交易所:
NYSE
成立时间:
1998
员工人数:
900
公司地址:
300 Professional Drive,Suite 400,Gaithersburg,Maryland,United States
邮编:
20879
电话:
传真:
240-631-3203
简介:
Emergent Biosolutions Inc.于1998年5月在美国密歇根州成立,随后在 2004年6月改为特拉华公司。公司拥有两个经营部门:生物防卫和生物科学。该公司是一家全球性生命科学公司,专注于提供创新的准备和响应解决方案,以应对意外、故意和自然发生的公共健康威胁。

董事

名称
职位
Joseph C. Papa
Director,Chief Executive Officer and President
Zsolt Harsanyi
Chairman of the Board and Independent Director
Donald DeGolyer
Independent Director
John D. Fowler, Jr.
Independent Director
Kathryn C. Zoon
Independent Director
Keith Katkin
Independent Director
Marvin L. White
Independent Director
Neal Fowler
Independent Director
Ronald B. Richard
Independent Director
Sujata Dayal
Independent Director

股东

名称
职位
Joseph C. Papa
Director,Chief Executive Officer and President
Jessica Perl
Senior Vice President, General Counsel and Corporate Secretary
Paul Williams
Senior Vice President, Products Business
Richard S. Lindahl
Chief Financial Officer and Executive Vice President
William Hartzel
Senior Vice President, Manufacturing and Bioservices
Coleen Glessner
Executive Vice President, Quality and Ethics and Compliance
Simon Lowry
Chief Medical Officer and Head of Research and Development